Member Info for olderbutwiser

It is now being increasingly stated that covid-19 will be a significant problem for the foreseeable future (many years).
So there is now rapidly growing interest in treatments for the damage inflicted on severely affected covid-19 patients, with lung damage ‘fibrosis’ being one of the widely reported issues.
Pharma’s will want to get the best of these treatments to market as quickly as possible for all the obvious commercial reasons.
It has been stated that NXP002 and NXP004 offer significantly superior efficacy with none of the severe side effects of the current market leader fibrosis drugs and almost as importantly they also offer faster speed to market and less risk with their cocrystal approach.
So drugs like NXP002 which are cocrystal modifications of existing proven ‘safe’ drugs that have already been through full clinical trials and have been in widespread use for some time are an obvious choice, as they offer many commercial benefits compared to taking a new drug form/ approach.
• clinical trials requirements are significantly reduced therefore speeding up time to market
• the risk of failure during clinical trials is much reduced
• the risk of unforeseen side effects being uncovered during clinical trials or once in the market with the attendant litigation and damages are also reduced.
So as well as the treatment benefits there are major commercial factors that should be playing to Nuformix’s advantage here.

So Nuformix now openly states that both their fibrosis drugs NXP002 and NXP004 are potential treatments for covid-19.

Until now Nuformix have been extremely cautious on this subject, but with two of their scientific advisors being world leading scientists in lung fibrosis then I reckon they must have some fairly strong evidence to support making these statements now, after all these guys reputations are potentially on the line.

Asia already had a big fibrosis problem and it has just got a whole lot worse and now the rest of the world and the US in particular has a much much bigger fibrosis problem. and now Nuformix say they are getting increased interest in these drugs.
Hardly surprising as Nuformix trials show NXP002 has far superior efficacy than the current market leaders and without the severe side effects associated with the current market leaders! So I wonder how good NXP004 must be if the BOD of Nuformix are really excited by its significant success so far in trials!

All we need is the first tell-tale signs of deals being done and I think this will get really quite exciting, and it sounds like deals are just around the corner!

Just looked at the video again and was intrigued.
Chris Blackwell seems to be a very level guy and saying it straight as it is., without any real emphasis anywhere.
The exception seemed to be when he was talking about nxp004 he said (at 06.30 mins in)
'We are reeaally excited about the potential for this candidate (nxp004) and again are looking at all options for deriving value from it'.
Any ideas re what fibrosis applications this could be for?

Soup
We have had nothing but rumours and silence for months and now there is so much info to review and evaluate.

Interesting find re new Non-executive director - I suppose they are a bit thin on the ground with directors now, so to be expected.
Intrigued by your comments on nxp001 and possible veterinary use - your rationale seems logical re how they worded the RNS sentence and your comments re the video - if its not humans that leaves animals, there again if its not animals then that just leaves aliens (huge market throughout the galaxy) but better not start off the UFO conspiracy brigade.

Mars1
Exactly why I am hoping they are now negotiating for nxp002 in the US as well and not just waiting on Kissei in japan. As someone else said we need to let them know there are people competing for nxp002 and moving things on now, which is what Chris Blackwell seems to be doing.

Soup.
Agree it would be nice to have more info on Ebers and Vistagen contracts, but presumably confidentiality is the issue here. So I do not read anything untoward in the situation. Hopefully more patents and milestone payments soon.

In the update from May 2020 they said

a further patent filing has been made in relation to novel cannabinoid cocrystals. This latest patent filing triggers an undisclosed development milestone payment.
Also that further cannabinoids have been added to the agreement, triggering additional undisclosed milestones and remain under development, with the potential for further milestone payments to Nuformix in the near-term.

https://youtu.be/K5wMQ2rCrHs

The problems that have severely affected Nuformix and frustrated investors have nearly all emanated from the China - in the form of the Newsummit non-payment and the major consequences of the COVID-19 virus on deal negotiations and clinical trials. These would be difficult to mitigate for any company, although in hindsight a bigger raise last year would have been prudent, but they have got through this period and appear to be in a stronger position with both their drugs pipeline and finances than they were a year ago when the sp was 14p.Just be nice if we avoid anything China related in the future, as it is just a world of pain and grief for companies and to be avoided like the proverbial plague.Anyway I have to ignore what has happened and look to future potential, and it is now a different company and from what I read the potential has increased significantly. Look forward to the next few months with interest.GLA

From todays RNS
interest in our assets and their potential in the treatment of COVID-19, as well as the resultant fibrosis, has increased. These business discussions are confidential and further announcements will be made as and when appropriate.'

NXP002 - Inhaled therapy for Fibrotic Diseases
Nuformix's NXP002 programme remains the Group's priority and entails the development of an inhaled therapy, initially for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Our focus is now on the development of a formulation and delivery process that exploits the optimal means to treat fibrosis of the lungs, through nebulisation of the drug to facilitate inhalation by the patient. We are considering a number of inhalation devices that would enable rapid and deep penetration of the drug into the lungs with a view to evaluating them further.
We have also started to review and assess some emerging academic data that suggest coronaviruses can trigger hyper-inflammation through activation of the biological target known as the NLRP3 inflammasome, making this a potential novel drug target to treat COVID-19. The mechanism of NXP002 can interact directly with NLRP3, blocking the assembly of the inflammasome. Whilst this still requires clinical validation, we intend to explore the commercial potential of this attribute of our drug.
The Group previously announced that negotiations for out-licensing commercial rights for Asia markets were underway. Discussions have continued but the pace of negotiations has been limited as a result of the COVID-19 pandemic situation, closures to key sites in Asia and access to key personnel. When normal trading conditions return, with direct access to key personnel, we hope to continue these and other efforts to derive value from this product for all key world markets. The value of NXP-002 is not just confined to Asia and we intend to assess interest in regions outside Asia with additional parties.
'We acknowledge that progress on business development deals has been slower than previously expected. In part, this is a result of the huge impact that the COVID-19 pandemic has had on business and societies across the world. We must also acknowledge that as a small emerging company, we are not in control of the pace of negotiations. This is not always a negative, as during this time, the interest in our assets and their potential in the treatment of COVID-19, as well as the resultant fibrosis, has increased. These business discussions are confidential and further announcements will be made as and when appropriate.'

Having considered this mornings information on NXP002 I am confident that they see a real opportunity here.
It seems they have been assessing NXP002 for treating COVID-19 patients for a while now, obviously with support and guidance from Dr Muhunthan Thillai who is the Lead Clinician for the Cambridge Interstitial Lung Disease Unit and Prof Derek Mann who is Director of the Newcastle Fibrosis Research Group (NFRG), who are both world leaders in their firlds and highly involved in COVID-19 treatment, and who are both scientific advisors to Nuformix. They must be fairly sure of its benefit for COVID-19 patients if these advisors are involved and advocating its potential use.

Unbelievable rubbish by those who obviously have not even read the RNS or who are deliberately misleading people .That is you Sonnets, Brooko19 and Cyprusjoe .From the RNS - The Board believes the Group has sufficient cash when combined with expected income to deliver on its objectives and following the Board's recent review of the Group's cash flow needs and opportunities.The Group is currently at a stage where the Board considers availability of cash to be the primary KPI. At 31 March 2020 cash balances totalled GBP543,772 (2019: GBP4,261).

That is the highlights. Will review the changes and RNS in slower time now over some breakfast.
We will see how market reacts in 40 minutes.
I think there are lots of positives although I am sure we would all, especially Goupplease, like everything to happen faster.
Even NXP004 completing later this year could well be a blessing as it enables the new improved formulations to be tested within the existing trials without having to wait for a new pre-clinical trials slot at NFRG.
Overall I think it is potentially really good and removes most of the unknowns and rumours being circulated.
Good luck all.

The Board believes the Group has sufficient cash when combined with expected income to deliver on its objectives and following the Board's recent review of the Group's cash flow needs and opportunities.
The Group is currently at a stage where the Board considers availability of cash to be the primary KPI. At 31 March 2020 cash balances totalled GBP543,772 (2019: GBP4,261).

Post-period in May 2020, the Group announced a new collaboration with VistaGen Therapeutics Inc. (VistaGen), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system "CNS" diseases and disorders with high unmet need. VistaGen will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of their AV-101 programme. If successful, Nuformix and VistaGen will consider opportunities to extend the collaboration to other CNS therapeutic candidates with a view to unlocking additional therapeutic and commercial opportunities. We hope to be in a position to announce the outcome over the next quarter.

'We acknowledge that progress on business development deals has been slower than previously expected. In part, this is a result of the huge impact that the COVID-19 pandemic has had on business and societies across the world. We must also acknowledge that as a small emerging company, we are not in control of the pace of negotiations. This is not always a negative, as during this time, the interest in our assets and their potential in the treatment of COVID-19, as well as the resultant fibrosis, has increased. These business discussions are confidential and further announcements will be made as and when appropriate.'

RNS for financials and pipeline update is out.

It is a bit galling that they took so long to state the NXP002 applicability to treating COVID-19 patients but they are scientists first and foremost and will not declare any anything unless they are pretty sure. So it seems they have been assessing NXP002 for treating COVID-19 patients for a while now, presumably with support and guidance from Dr Muhunthan Thillai who is the Lead Clinician for the Cambridge Interstitial Lung Disease Unit and Prof Derek Mann who is Director of the Newcastle Fibrosis Research Group (NFRG) and who are both scientific advisors to Nuformix. They must be fairly sure of its benefit for COVID-19 patients if these advisors are involved.

The pre-clinical trials will now complete by the end of 2020 to enable evaluation of the pre-clinical data alongside exploring new formulation options with our cocrystal forms and will enable us to begin to explore additional business development options. So we know the results are really good for NXP004 and the continuation of pre-clinical trials will allow the testing of additional new formulation options. I read this as a positive as the initial delay has enabled Joanne Holland and her team to improve the formulation of NXP004 even further and utilise the existing delayed pre-clinical trials at NFRG to assess these improvements. Although not explicitly stated NXP004 I am guessing NXP004 may also be a suitable treatment for COVID-19 patients. The completion of NXP004 pre-clinical trials was previously delayed by COVID-19 issues at NFRG, which was totally beyond Nuformix’s or NFRG’s control, however the currently available preliminary data from these trials is extremely encouraging with NXP004 showing a significantly superior anti-fibrotic action compared to currently approved therapies and without the severe adverse effects seen with currently therapies.

NXP004 is now identified as a fibrosis drug for multiple forms of fibrosis.
As previously stated initial data from pre-clinical trials shows that NXP004 has a significantly superior anti-fibrotic action compared to currently approved therapies.